TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01481961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
Study: NCT05673772

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short-course radiotherapy
Description: 25 Gy in 5 fractions for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Oxaliplatin 85 mg/m2, Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2, 5- FU 400 mg/m2, and continuous 5- FU 2,400 mg/m2 for 46 hours

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: 45\~50.4 Gy/25fr with concurrent use of either capecitabine or 5-FU+leucovorin(or levoleucovorin or leucosodium)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME surgery
Description: TME surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME surgery
Description: TME surgery
Study: NCT00398749

Intervention type: DRUG
Intervention: Epoetin alfa
Description: 40,000 IU once weekly, variable treatment length
Study: NCT01800903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath catheter
Description: The Speedicath cathere is CE-marked and commercially available.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath catheter
Description: The Speedicath cathere is CE-marked and commercially available.
Study: NCT02316717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM-124E
Description: IMM-124E

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM-124E
Description: IMM-124E

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT02333916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overfeeding + exercise pre-training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fitness training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overfeeding + exercise post-training
Study: NCT02591628

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ prescription conversion to chlorthalidone
Description: The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
Study: NCT01950546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanosilver fluoride
Description: The product will be applied in the volunteers in the morning, before the first class, in relative isolation, made with cotton rolls and Vaseline to protect the soft tissue. It will apply 30mg of the product with microbrush, previously standardized in a pilot study on cervical vestibular surfaces of incisors and canines healthy, on a total of 8 teeth, 4 upper and 4 lower. After a period of 7 days,the cervical dental biofilms will be collect, third on the buccal surfaces of incisors and / or canines upper and lower, with the aid of sterile spatulas.
Study: NCT00261924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion of Pathogen Inactivated Platelets stored for 6-7 days
Description: pathogen inactivation of platelets for transfusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transfusion of Pathogen Inactivated Platelets stored for 6-7 days
Description: pathogen inactivation of platelets for transfusion
Study: NCT03268967

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured admission procedure
Description: A structured ICU admission was inspired by principles of Crisis Resource Management and simulation training of ICU staff members. The Principles of Crisis Resource Management consisted of a treatment manual, a learning video, clear precise communication tool based on Identification-Situation-Background-Analysis-Recommendations (ISBAR) and Closed loop, actions cards, and ABCDE-evaluation of the patient including debriefing, and training in the simulation environment.
Study: NCT03339375

Intervention type: DEVICE
Intervention: esophageal Doppler
Description: Goal directed fluid therapy using dynamic parameters from esophageal Doppler
Study: NCT00650039

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
Study: NCT01565135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Vaccine Program
Description: Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:~* Patient education regarding the importance of vaccination, including encouragement of vaccination for family members~* Practice-based reminder/recall~* Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback
Study: NCT02423265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo: up-titration after 1 week
Study: NCT02064738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams
Study: NCT01486017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study: NCT02148835

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sausage: Triomeg
Description: Commercial sausages enriched with 330 - 510 mg EPA+DHA / 100 g Approximate average composition of active product per 80 g Sausage (Triomeg): 250 mg EPA+DHA as ethyl-ester Energy content 500 kJ (120 kcal), protein 12 g, Carbohydrates 0.8 g, total fat 9 g, of which 2.8 g saturated fatty acids, 4.5 g monounsaturates, 1.4 g polyunsaturates. sodium 0.66 g.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sausage: Control
Description: Control sausage: as active, but no EPA+DHA ethyl-ester.
Study: NCT01486017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study: NCT04623580

Intervention type: DEVICE
Intervention: Surgical inguinal or femoral hernia repair
Description: Surgical inguinal or femoral hernia repair (primary or mesh)
Study: NCT03982329

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: navigated repetitive transcranial magnetic stimulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: physical therapy
Study: NCT01221974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Essure Micro Insert
Study: NCT02420496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteral fish oil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02531165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 500 mg loading dose orally (or intravenously), followed by 100 mg od

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 500 mg loading dose orally (or intravenously), followed by 100 mg od

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractioned Heparin
Description: 5'000 IU loading dose intravenously, additional doses to achieve an ACT \>250 sec during PCI are allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractioned Heparin
Description: 5'000 IU loading dose intravenously, additional doses to achieve an ACT \>250 sec during PCI are allowed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary PCI
Description: Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary PCI
Description: Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.
Study: NCT02797262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proteus digital health feedback (PDHF) system
Description: Building on the available Proteus devices, the investigators will design and create a PDHF system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
Study: NCT00841438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotinab
Description: Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotinab
Description: Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
Study: NCT01043965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850mg
Study: NCT01445392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multicycle SS1P
Description: Assigned dose level of SS1(dsFv)PE38 on days 1, 3 \&amp; 5 of a 21 day cycle for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 on day 1 of each 21 day cycle until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 on day 1 of each 21 day cycle until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m\^2 on day 1 of each 21 day cycle until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m\^2 on day 1 of each 21 day cycle until disease progression

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single cycle SS1P
Description: Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
Study: NCT00844792

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E
Description: Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day with meals.
Study: NCT03372512

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioimpedance spectroscopy
Description: Fluid overload will be assessed by bioimpedance spectroscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioimpedance spectroscopy
Description: Fluid overload will be assessed by bioimpedance spectroscopy
Study: NCT02283502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgHIFU system
Description: Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
Study: NCT01719692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study: NCT03929835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis oil
Description: T1/C20 CBD
Study: NCT02684526

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eovist Contrast
Description: Subjects will undergo an MRI (magnetic resonance imaging) scan using the Eovist contrast agent. This MRI scan takes approximately 45minutes to 1 hour to complete.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non Eovist Contrast
Description: Subjects will undergo an MRI (magnetic resonance imaging) scan using a contrast agent other than Eovist. This MRI scan takes approximately 45minutes to 1 hour to complete.
Study: NCT03929835

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil with chlorophyl
Study: NCT01899469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Therapy
Description: 20 sessions from Monday to Friday of 20 minutes of Electromagnetic Therapy, using the next parameters: 10 Hz of frequency and 60% of intensity, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Neurological Stimulation
Description: Procedure/Surgery: Transcutaneous Electrical Neurological Stimulation (TENS)~20 sessions from Monday to Friday of 20 minutes of TENS Therapy using the next parameters: 100μs of impulse width, 80 Hz of impulse frequency, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Back School
Description: 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Back School
Description: 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Back School
Description: 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
Study: NCT01994304

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCC
Description: The intervention involves introducing and orienting health providers on the SCC, facilitating availability of a specific set of commodities and regular targeted supervision. These are expected to improve adherence to life saving interventions immediately before, during and after birth, and reduce intrapartum mortality (still births and very early neonatal deaths).
Study: NCT00554749

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interventions at home, in the kindergarten/school
Description: Weekly interventions including behavior techniques (stimulus fading)
Study: NCT02031445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-6

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02267746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene (Fabior™)
Study: NCT00943826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m\^2 once daily for 6 weeks, followed by 150-200 mg/m\^2 once daily on days 1-5 of six 4 week cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: 75 mg/m\^2 once daily for 6 weeks, followed by 150-200 mg/m\^2 once daily on days 1-5 of six 4 week cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation therapy
Description: 30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
Study: NCT02267746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene (Actavis)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Study: NCT00050167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks
Study: NCT05716711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LAVENDER OIL
Description: IT WILL BE APPLIED TO 60 PATIENTS, 20 IN EACH GROUP, WITH A COLOSTOMY
Study: NCT00050167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 by vein (IV) Over 1 Hour Once Every 3 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1500 mg/m\^2 by mouth Twice Daily x 2 Weeks
Study: NCT00689481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U0267 Foam
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
Study: NCT04099524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS (LPG/C3-anode, orbitofrontal cortex/Fp2-cathode) will be administered for 4 weeks (1 session per weekday for 2 weeks, and then 2 sessions per week for 2 weeks, for a total of 14 sessions). All subjects will receive anodal tDCS stimulation for 20 minutes per session, on C3 and the cathode electrode on Fp2 using 10/20 EEG system. tDCS will be applied with a pair of 35 cm2 single-use sponges soaked in approximately 4mL of saline solution on each side (\~8mL per sponge) connected to the stimulator. During the 20-minute tDCS session, we will use online tDCS design (i.e., a subject will simultaneously work on the visual attention-oriented task.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS (LPG/C3-anode, orbitofrontal cortex/Fp2-cathode) will be administered for 4 weeks (1 session per weekday for 2 weeks, and then 2 sessions per week for 2 weeks, for a total of 14 sessions). All subjects will receive anodal tDCS stimulation for 20 minutes per session, on C3 and the cathode electrode on Fp2 using 10/20 EEG system. tDCS will be applied with a pair of 35 cm2 single-use sponges soaked in approximately 4mL of saline solution on each side (\~8mL per sponge) connected to the stimulator. During the 20-minute tDCS session, we will use online tDCS design (i.e., a subject will simultaneously work on the visual attention-oriented task.
Study: NCT02188381

Intervention type: OTHER
Intervention: Stool Sample and Blood Sample
Description: All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.

Intervention type: OTHER
Intervention: Stool Sample and Blood Sample
Description: All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.

Intervention type: OTHER
Intervention: Stool Sample and Blood Sample
Description: All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.

Intervention type: OTHER
Intervention: Stool Sample and Blood Sample
Description: All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.

Intervention type: OTHER
Intervention: Stool Sample and Blood Sample
Description: All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.
Study: NCT04230642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Quantum Surgical device
Description: Robotic platform for needle placement
Study: NCT04232163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm Boot Camp
Description: The intervention involves a combination of daily homework based upper limb exercises and feedback from an activity monitor to motivate use of the affected upper limb. Participants will be supported through virtual sessions with a therapist.